COMMUNIQUÉS West-GlobeNewswire

BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
15/05/2026
SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
15/05/2026
Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, [...]
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
15/05/2026
Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial First interim unblinding expected in June 2026 following 45 subject enrollment milestone [...]
LifeMD to Participate in Upcoming Investor Conferences
15/05/2026
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading platform for virtual primary care services, today announced that management will be participating in two upcoming investor conferences. [...]
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
15/05/2026
NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business [...]
CytoDyn to Present at the LD Micro Invitational XVI
15/05/2026
CFO Robert E. Hoffman to deliver company presentation on May 18 at 10 a.m. PT VANCOUVER, Washington, May 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology [...]
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
15/05/2026
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Capital Markets [...]
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
15/05/2026
Federal Officials, Researchers, Clinicians and Biopharma Leadership Convene d by Psychedelic Medicine Coalition at the National Press Club Vancouver, Canada, May 15, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( [...]
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
15/05/2026
Completed enrollment in first cohort of Phase 1b challenge study evaluating CDI-988 as a preventive and as a treatment for norovirus infection, began enrollment in prevention and treatment cohorts Highlighted CDI-988’s [...]
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
15/05/2026
WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported [...]
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
15/05/2026
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat [...]
Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu
15/05/2026
Conference call and live webcast to be held Monday, May 18 th at 3:00pm ET Wall Street firm publishes research report refuting claims made by recent unaffiliated third-party article; Research report also references [...]
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
15/05/2026
Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS- [...]
Vaso Corporation Announces Financial Results for First Quarter of 2026
15/05/2026
PLAINVIEW, N.Y., May 15, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional sales services, and [...]
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
15/05/2026
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the first quarter ended [...]
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
15/05/2026
All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies Provide Evidence of [...]
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
15/05/2026
Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026 BASECAMP remains on track to complete enrollment in Q3 2026 The Company has initiated the TRAILHEAD [...]
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
15/05/2026
FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer’s dementia Evaluating [...]
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
15/05/2026
Q1 2026 total revenue of $22.7 million including neffy ® (epinephrine nasal spray) U.S. net product revenue of $17.5 million CVS Caremark proposal in final stages of approval process; definitive update anticipated in [...]

Pages